31.1 C
New York
Saturday, June 13, 2026

Tag: glucose

QNET Unveils Wellness Breakthroughs and Global Empowerment at V-Malaysia 2025

Over 8,000 global entrepreneurs gather in Penang for five days of wellness innovation and mentorship. HONG KONG, July 11, 2025 /PRNewswire/ -- QNET kicked off...

Cancer Cachexia Market Anticipates Impressive Growth Trajectory at a CAGR of 8.9% During the Forecast Period (2025-2034) | DelveInsight

The cancer cachexia market is expected to witness an expansion across the 7MM, driven by the introduction of innovative therapies, ponsegromab (PF-06946860), S-pindolol benzoate...

Cancer Cachexia Market Anticipates Impressive Growth Trajectory at a CAGR of 8.9% During the Forecast Period (2025-2034) | DelveInsight

The cancer cachexia market is expected to witness an expansion across the 7MM, driven by the introduction of innovative therapies, ponsegromab (PF-06946860), S-pindolol benzoate...

Glucostra Launches Plant-Based Formula with 20 Ingredients for Natural Blood Sugar and Glucose Balance Support

Clean-Label Botanical Formula Aligns with 2025 Demand for the Best Natural Ingredients in Blood Sugar and Glucose Balance SupportSan Francisco
Clean-Label Botanical Formula Aligns with 2025 Demand for the Best Natural Ingredients in Blood Sugar and Glucose Balance SupportSan Francisco

Emergent BioSolutions Secures $51.9 Million Contract Modification Award for CNJ-016® [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV) as part of U.S. Biodefense Preparedness Efforts

GAITHERSBURG, Md., July 08, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced a contract modification has been secured to deliver CNJ-016® [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV) to the Administration for Strategic Preparedness and Response (ASPR), part of the U. S. Department of Health and Human Services (HHS), for smallpox preparedness. ASPR exercised an option from its existing 10-year contract (75A50119C00037) for additional doses of VIGIV, a treatment for complications due to smallpox vaccination.

Biosensors Market worth $54.37 billion by 2030 – Exclusive Report by MarketsandMarkets™

DELRAY BEACH, Fla., July 8, 2025 /PRNewswire/ -- The global biosensors market is projected to grow from USD 34.51 billion in 2025 to USD 54.37...

Biosensors Market worth $54.37 billion by 2030 – Exclusive Report by MarketsandMarkets™

DELRAY BEACH, Fla., July 8, 2025 /PRNewswire/ -- The global biosensors market is projected to grow from USD 34.51 billion in 2025 to USD 54.37...

SlimJaro Botanical Approaches Gain Interest in 2025 for Inflammation-Related Metabolic Wellness

A new category of plant-based formulations is gaining attention for their role in supporting internal balance and inflammation-linked metabolic concerns. Among these is SlimJaro, which features botanical ingredients studied for their relation to digestion, inflammation, and cortisol support
A new category of plant-based formulations is gaining attention for their role in supporting internal balance and inflammation-linked metabolic concerns. Among these is SlimJaro, which features botanical ingredients studied for their relation to digestion, inflammation, and cortisol support

WST INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that West Pharmaceutical Services, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action...

NEW YORK, July 06, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against West Pharmaceutical Services, Inc. (“West” or “the Company”) (NYSE: WST) and certain of its officers.

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of West Pharmaceutical Services

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In West To Contact Him Directly To Discuss Their Options

Remote Pharmacy Releases 2025 Availability Update on GLP-1 Weight Loss Solutions and Consumer Interest in Semaglutide & Tirzepatide

In this 2025 availability update, Remote Pharmacy highlights the expanded access to non-branded GLP-1-based weight management options, including semaglutide and tirzepatide compounds. The release explores the evolving role of compounded therapeutics, shifts in consumer behavior toward remote prescribing, and how new formulations align with the growing interest in safe, physician-directed care for weight management.
In this 2025 availability update, Remote Pharmacy highlights the expanded access to non-branded GLP-1-based weight management options, including semaglutide and tirzepatide compounds. The release explores the evolving role of compounded therapeutics, shifts in consumer behavior toward remote prescribing, and how new formulations align with the growing interest in safe, physician-directed care for weight management.

Gluco6 Recognized for Strong Ingredient Transparency and OTC GLUT-4 Nutritional Support

Featuring Sukre™ for GLUT-4 Receptor Support, Gluco6 Highlights Non-Synthetic Compounds and 2025 Trends in Plant-Based Glucose Wellness
Featuring Sukre™ for GLUT-4 Receptor Support, Gluco6 Highlights Non-Synthetic Compounds and 2025 Trends in Plant-Based Glucose Wellness

PhenQ Updates 2025 Formula With Strongest OTC Appetite Suppressant Profile and Clinically Studied Craving Support Ingredients

Now Reformulated With InnoSlim®, α-Lacys Reset®, and Capsimax® to Support Multi-Pathway Metabolic Function Without a Prescription
Now Reformulated With InnoSlim®, α-Lacys Reset®, and Capsimax® to Support Multi-Pathway Metabolic Function Without a Prescription

WST DEADLINE: ROSEN, A LONGSTANDING FIRM, Encourages West Pharmaceutical Services, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important July...

NEW YORK, July 02, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of West Pharmaceutical Services, Inc. (NYSE: WST) between February 16, 2023 and February 12, 2025, both dates inclusive (the “Class Period”), of the important July 7, 2025 lead plaintiff deadline.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsGlucose